Drugs / Autologous Stem Cell Transplantation
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00550498 | Dec 2007 → Jul 2012 | Behcet disease, retinitis | Tehran University of Medical Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT00550524 | Dec 2007 → Nov 2010 | osteoarthritis, knee | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02326662 | Jul 2014 → Oct 2018 | spinal cord injury | Federal Research Clinical Center of Federal Medical & Biological Agency, Russia | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Stem Cell Transplantation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02326662 ↗ |
| Modality | Cell therapy | “Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet's disease retinal vasculitis” PMID 23773637 ↗ Apr 2013 |
| Route | Other | “Cells will be injected in the knee joint with a 21 gauge needle.” NCT00550524 ↗ |